Key takeaways
- A significant financial interest has a specific federal definition, not an institutional judgment call: any equity in a private entity, or $5,000 or more in aggregate remuneration from a publicly traded entity in a 12-month period, and a disclosure process that treats every interest identically misses that the threshold itself determines whether disclosure is even required.
- Institutional conflicts of interest, where the institution itself, not just the researcher, has a financial stake in a study's outcome, are a distinct category almost no COI office tracks with the same rigor as individual disclosures, even though the same federal rule requires it.
- Invention disclosure runs on its own separate, unforgiving clock: two months from an inventor's written disclosure to the institution, and two years from the institution's disclosure to the funding agency to elect whether to retain title, a timeline that does not wait for the COI review to finish first.
Why a COI disclosure is a timing problem as much as a content problem
A researcher discloses an outside consulting relationship, and the disclosure itself is straightforward: the entity, the relationship, the estimated value. What determines whether that disclosure creates real institutional risk is not the content alone. It is whether the disclosure happened when it was supposed to, at proposal submission, at least annually, or within the institution's policy window after a new interest arose, and whether the institution reviewed and, if necessary, managed it within the federally required window. A COI system that captures accurate disclosures but cannot show they were reviewed on time has captured half the compliance obligation.
What actually counts as a significant financial interest
The threshold is not a matter of institutional discretion. Under 42 CFR 50.603, a significant financial interest includes any equity interest or stock option in a private entity, aggregate remuneration of $5,000 or more in a 12-month period from a publicly traded entity, consulting fees, royalties, board or advisory positions, and sponsored or reimbursed travel tied to the researcher's role. Under 42 CFR 50.604, institutions must solicit disclosures at proposal submission, at least annually, and within a defined window of a new interest arising, and must review and determine within 60 days of discovering a conflict whether it requires a management plan. A COI office that reviews a disclosure eventually, but not within that 60-day window, has created a compliance gap independent of what the disclosure actually contained.
Institutional conflicts: the category most COI offices don't formally track
An institutional conflict of interest is different from an individual researcher's disclosure: it exists when the institution itself holds a financial stake that could bias the research, equity in a startup licensing the institution's own technology, or the institution serving as a co-investigator on a study it also stands to benefit from financially. This category is harder to identify than an individual's disclosure because no single researcher is the one who discloses it, and most COI offices have no formal process to surface it beyond an individual researcher happening to mention the institutional relationship in their own disclosure. A COI program that only tracks individual disclosures has structurally excluded the conflict category federal rules also require it to manage.
IP disclosure runs on a separate, unforgiving clock
A potential invention triggers its own compliance obligation, independent of and running in parallel to any COI review the same researcher is going through. Under 37 CFR 401.14, an institution must disclose a subject invention to the funding agency within two months of the inventor's written disclosure to the institution's own patent personnel, and if the institution elects to retain title, that election has to be made within two years of the disclosure to the agency. These two clocks, COI's 60-day review window and Bayh-Dole's two-month and two-year deadlines, do not synchronize automatically, and a researcher whose invention disclosure and financial disclosure both touch the same outside company needs both processes tracked together, not as two unrelated cases that happen to share a name.
Disclosure type, threshold, and deadline
Disclosure type
|
Threshold or trigger
|
Deadline
|
|
Individual financial interest
|
Any equity in a private entity, or $5,000+ from a public entity
|
Reviewed within 60 days of discovery
|
|
Institutional conflict
|
Institution holds a financial stake in the research outcome
|
No fixed federal deadline; requires proactive identification
|
|
Invention disclosure to the institution
|
Inventor identifies a potential subject invention
|
Institution discloses to the agency within 2 months
|
|
Election of title
|
Institution decides whether to retain patent rights
|
Within 2 years of disclosure to the agency
|
A governed COI and IP disclosure workflow
Disclosures are checked against the federal threshold automatically
A submitted interest is evaluated against the equity and dollar thresholds that determine whether it qualifies as significant, rather than relying on the researcher's own judgment about whether something is worth disclosing.
The 60-day review clock starts at discovery, not at convenience
A disclosure requiring review is tracked against its actual 60-day window, with the determination and any management plan recorded before that window closes.
Institutional conflicts are actively surfaced, not passively awaited
When a disclosure references a relationship the institution itself also holds, such as a licensing arrangement or an equity stake, the workflow flags it for institutional conflict review specifically.
Invention disclosures start their own independent clock
A reported potential invention triggers the two-month disclosure deadline to the funding agency immediately, tracked separately from any related COI review touching the same researcher or entity.
Related COI and IP cases are linked, not siloed
When a financial disclosure and an invention disclosure both involve the same outside company, the workflow connects the two cases so a reviewer sees the full picture rather than two disconnected files.
Every determination and election is retained with its rationale
Management plan decisions and title election choices are documented and retained for at least three years, producing the record an audit or a sponsor review would sample.
Kissflow and the COI and IP disclosure stack
Kissflow is the governed execution layer at the edges of the COI and IP disclosure stack. It does not replace the COI committee's judgment or the technology transfer office's patent strategy. It replaces the disconnected intake forms and spreadsheets that currently make it possible for a financial disclosure and a related invention disclosure to be reviewed as if they had nothing to do with each other.
If your institution runs Cayuse COI or a similar dedicated system, Kissflow does not compete with it for disclosure intake. It sits alongside it as the layer that enforces the 60-day review clock, surfaces institutional conflicts proactively, and connects a researcher's financial and invention disclosures when they touch the same underlying relationship.
The differentiation that matters to a compliance office: when federal thresholds change or the institution adjusts its own management plan process, that office updates the workflow directly, instead of retraining every department on a threshold a generic form was never built to enforce automatically.
Frequently asked questions
1. What dollar amount triggers a financial disclosure requirement?
Under 42 CFR 50.603, any equity interest in a private entity requires disclosure regardless of value. For a publicly traded entity, the threshold is $5,000 or more in remuneration and the value of any equity interest, combined, within a 12-month period.
2. How quickly does an institution have to review a disclosed conflict?
Within 60 days of discovering it, a deadline that runs from the date the institution learns of the interest, not from a convenient batch review cycle.
3. What makes an institutional conflict different from an individual researcher's disclosure?
An institutional conflict exists when the institution itself, not just the researcher, holds a financial stake in the research outcome, such as equity in a company licensing the institution's own technology. It requires separate identification because no individual researcher's disclosure automatically surfaces it.
4. How long does an inventor have to disclose a potential invention?
The institution must disclose a subject invention to the funding agency within two months of the inventor's written disclosure to the institution's own patent personnel.
5. Does a COI review need to wait for an invention disclosure to finish, or vice versa?
No, the two run on independent clocks, but when they involve the same outside relationship, they should be tracked together so a reviewer sees the connection rather than two unrelated cases.
6. Does Kissflow replace our COI disclosure system?
No. Kissflow is the workflow layer that enforces review deadlines, surfaces institutional conflicts, and connects related COI and IP cases. A dedicated COI system, where one exists, remains the system of record for the underlying disclosures.
Request a 30-minute walkthrough to see how Kissflow routes COI and invention disclosures through the exact thresholds and deadlines federal rules require.
